Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Yisheng Granted US Orphan Drug Designation for Rabies Vaccine

publication date: Jan 4, 2017
Yisheng Biopharma of Beijing was granted US Orphan Drug designation for its lead vaccine candidate, a novel PIKA rabies vaccine. The vaccine, which uses Yisheng's proprietary toll-like receptor-3 (TLR-3) activation technology, is currently in Phase II trials. The PIKA vaccine requires only three injections in seven days, as opposed to the usual regimen of five shots over 28 days. In the Phase I trial, it created a faster response to rabies infection. Three months ago, Yisheng was granted US Orphan Drug designation for its livery cancer immunotherapy. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital